Strategy

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

Two words define the future of commercialization project management: Faster and Better

partnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity

Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.

MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.

California's Bay Area and the Boston/Cambridge nexus continue to dominate bioinnovation in the US. Pharm Exec looks at the factors contributing to the strategic dominance of these regions.

Profitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge-and a lead position in the hotly contested search to make cancer a treatable disease.

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive - muddling through is so yesterday.

Successful innovation now has to align with key metrics of value-can an old baseball metaphor help guide the way?

Biopharma's best companies provide valuable lessons for preparing, planning, and playing to win. Stan Bernard shows us how.

Failure to improve successful launch rates will doom your company to marginalization in the fight for brand affinity - not to mention the prescriber loyalty that keeps medicines in play for the long haul.

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible-hope.

Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product

New drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.

Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share.

With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided.

Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.

As growth in the BRICs and other emerging economies begins to stabilize, companies are finally turning their attention to Africa-a hidden trove of potential that is only as good as you make it.

The lifeblood of the life sciences industry is continuous innovation-it is not a business that can survive by standing still.

Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.

Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage.

New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.

What is industry icon Fred Hassan's management formula for staying fresh in an era of market churn?

New approaches to managing reimbursements for pharmacy benefit programs are testing Big Pharma.

In the world of patient education, processes, policies, and oversight differ vastly. There is no overarching governance structure. There isn't an accreditation process for educational interventions or patient advocacy organizations that develop the education.

Companies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual.

Ken Getz of the Tufts University Center for the Study of Drug Development (CSDD) explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol.

A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.

Timely engagement is the key to expanding the use of companion diagnostics.